San Francisco startup Composition Therapeutics can also be working on an oral, when-daily GLP-one drug named GSBR-1290—the drug surpassed Wall Street’s expectations in June whenever a mid-stage study showed normal weight loss of all over 6% and it programs to get started on Yet another mid-phase trial in the direction of the top of this year—